Cariprazine as adjunctive treatment for depression symptom clusters: pharmacological profile and clinical evidence

This review examines cariprazine, a D2/D3 partial agonist atypical antipsychotic, as a potential adjunctive treatment for major depressive disorder patients with inadequate response to standard antidepressants. Preliminary evidence suggests cariprazine may improve motivation, anhedonia, and cognitive symptoms, though its effects on anxiety, agitation, and psychomotor symptoms remain uncertain.